Uncategorised - European Medical Journal

Gut Microbiota Predicts Cardiometabolic Disease Risk - EMJ

Specific Gut Microbes Linked to Cardiometabolic Disease Risk

Analysis revealed that a higher abundance of Eubacterium xylanophilum group spp. and Akkermansia muciniphila was associated with a lower risk of MACE+, whereas Ruminococcus gnavus group spp. was linked to higher MACE risk.

Hema Now: A Conversation with the EAHAD President

In this episode of Hema Now, Ana Boban discusses her vision as the incoming European Association for Haemophilia and Allied…

Zorevunersen Results in Dravet Syndrome - EMJ

Early Trials Highlight Zorevunersen Potential in Dravet Syndrome

Clinical studies suggest zorevunersen could reduce seizures and improve quality of life for children and adolescents with Dravet syndrome.

A dollar note with pills and capsules

Survey: Half of US adults struggle to afford healthcare

The share of Americans who feel financially secure about paying for basic healthcare has fallen to its lowest level since 2021.

AMR Governance Improving, But Resistance Still Rising - EMJ

AMR Governance Improving, But Resistance Still Rising

Global AMR governance has improved, but antimicrobial resistance remains high, highlighting gaps in policy implementation and surveillance.

Ammonia Buildup linked to Liver Tumours in Mice - EMJ

Ammonia Buildup Linked to Liver Tumours in Mice

Mouse study finds impaired ammonia clearance can accelerate hepatocellular carcinoma growth and highlights potential dietary strategies to slow tumours.

Ultrasound Characterisation of Uterine Fibroids - EMJ

Ultrasound Characterisation of Uterine Fibroids

Analysis of fibroid subtypes reveals unique ultrasound patterns and clinical profiles, helping differentiate usual-type from variant uterine fibroids.

Revisiting Erythroid Response to Luspatercept in the Phase III BELIEVE Trial Using Real-World Response Criteria

Patients with TDT have impaired erythropoiesis and face a chronic treatment burden of regular transfusions and iron chelation therapy to…

Sibeprenlimab Trial Shows Benefit in IgA Nephropathy - EMJ

UKKW 2026: Sibeprenlimab Reduces Proteinuria in IgA Nephropathy Trial

Interim results from the Phase III VISIONARY trial show that sibeprenlimab significantly reduced proteinuria and improved disease biomarkers in patients with IgA nephropathy.

Weight Loss Drugs May be More Effective in Women than Men

GLP-1RAs produce greater weight loss results among women than men, a 2026 systematic review and meta-analysis has found.